BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 11069439)

  • 1. Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD.
    Kirchner GI; Winkler M; Mueller L; Vidal C; Jacobsen W; Franzke A; Wagner S; Blick S; Manns MP; Sewing KF
    Br J Clin Pharmacol; 2000 Nov; 50(5):449-54. PubMed ID: 11069439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LC/ESI-MS allows simultaneous and specific quantification of SDZ RAD and cyclosporine, including groups of their metabolites in human blood.
    Kirchner GI; Vidal C; Winkler M; Mueller L; Jacobsen W; Franzke A; Sewing KF
    Ther Drug Monit; 1999 Feb; 21(1):116-22. PubMed ID: 10051064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.
    Neumayer HH; Paradis K; Korn A; Jean C; Fritsche L; Budde K; Winkler M; Kliem V; Pichlmayr R; Hauser IA; Burkhardt K; Lison AE; Barndt I; Appel-Dingemanse S
    Br J Clin Pharmacol; 1999 Nov; 48(5):694-703. PubMed ID: 10594471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability.
    Hausen B; Ikonen T; Briffa N; Berry GJ; Christians U; Robbins RC; Hook L; Serkova N; Benet LZ; Schuler W; Morris RE
    Transplantation; 2000 Jan; 69(1):76-86. PubMed ID: 10653384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation.
    Schuurman HJ; Ringers J; Schuler W; Slingerland W; Jonker M
    Transplantation; 2000 Mar; 69(5):737-42. PubMed ID: 10755519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine.
    Hausen B; Boeke K; Berry GJ; Segarra IT; Christians U; Morris RE
    J Heart Lung Transplant; 1999 Feb; 18(2):150-9. PubMed ID: 10194039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine.
    Serkova N; Hausen B; Berry GJ; Jacobsen W; Benet LZ; Morris RE; Christians U
    J Pharmacol Exp Ther; 2000 Jul; 294(1):323-32. PubMed ID: 10871329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats.
    Crowe A; Bruelisauer A; Duerr L; Guntz P; Lemaire M
    Drug Metab Dispos; 1999 May; 27(5):627-32. PubMed ID: 10220493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients.
    Kahan BD; Wong RL; Carter C; Katz SH; Von Fellenberg J; Van Buren CT; Appel-Dingemanse S
    Transplantation; 1999 Oct; 68(8):1100-6. PubMed ID: 10551636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural elucidation by electrospray mass spectrometry: an approach to the in vitro metabolism of the macrolide immunosuppressant SDZ RAD.
    Vidal C; Kirchner GI; Sewing KF
    J Am Soc Mass Spectrom; 1998 Dec; 9(12):1267-74. PubMed ID: 9835072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
    Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates.
    Serkova N; Litt L; Leibfritz D; Hausen B; Morris RE; James TL; Benet LZ; Christians U
    Br J Pharmacol; 2000 Feb; 129(3):485-92. PubMed ID: 10711346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients.
    Budde K; Lehne G; Winkler M; Renders L; Lison A; Fritsche L; Soulillou JP; Fauchald P; Neumayer HH; Dantal J;
    J Clin Pharmacol; 2005 Jul; 45(7):781-91. PubMed ID: 15951468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
    Schädeli F; Marti HP; Frey FJ; Uehlinger DE
    Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Automated simultaneous quantification of the immunosuppressants 40-O-(2-hydroxyethyl) rapamycin and cyclosporine in blood with electrospray-mass spectrometric detection.
    Vidal C; Kirchner GI; Wünsch G; Sewing KF
    Clin Chem; 1998 Jun; 44(6 Pt 1):1275-82. PubMed ID: 9625053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo.
    Schuler W; Sedrani R; Cottens S; Häberlin B; Schulz M; Schuurman HJ; Zenke G; Zerwes HG; Schreier MH
    Transplantation; 1997 Jul; 64(1):36-42. PubMed ID: 9233698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.
    Park JW; Siekmeier R; Merz M; Krell B; Harder S; März W; Seidel D; Schüler S; Gross W
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):439-50. PubMed ID: 12395976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of acute, ongoing rat lung allograft rejection with the novel immunosuppressant SDZ-RAD.
    Hausen B; Boeke K; Berry GJ; Christians U; Schüler W; Morris RE
    Ann Thorac Surg; 2000 Mar; 69(3):904-9. PubMed ID: 10750781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl)rapamycin.
    Segarra I; Brazelton TR; Guterman N; Hausen B; Jacobsen W; Morris RE; Benet LZ; Christians U
    J Chromatogr B Biomed Sci Appl; 1998 Dec; 720(1-2):179-87. PubMed ID: 9892080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification and stability of everolimus (SDZ RAD) in human blood by high-performance liquid chromatography-electrospray tandem mass spectrometry.
    Salm P; Taylor PJ; Lynch SV; Pillans PI
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Jun; 772(2):283-90. PubMed ID: 12007773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.